AzTrials
AzTrials

Diastolic Heart FailureNCT02315859

Validation of New Non-Invasive Parameters of Diastolic Suction in the Left Ventricle

An observational study of Diastolic Heart Failure, run by Insel Gruppe AG, University Hospital Bern at 1 site in Switzerland.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

It is known that, at the end of the cardiac ejection period, potential energy is stored in elastic fibers of the heart, which promotes the suction of blood from the atria during early filling. The investigators have developed a new ultrasound-based method to quantify this suction effect. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Diastolic Heart Failure
How many people
40 participants
Where
1 siteSwitzerland
Study dates
31 Dec 2014to 30 Jun 2017
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Study population: Population with a large variety of clinical conditions leading to dyspnea (for example hypertensive or hypertrophic heart disease, dilated cardiomyopathy), and where no significant coronary artery disease or regional wall-motion abnormalities are identified.

Who may be able to join

  • 1. Patients referred to elective percutaneous coronary angiography
  • Stable cardio-pulmonary conditions
  • Sinus rhythm
  • Written informed consent to participate to the study

Who cannot join

  • Patients referred to emergency coronary intervention
  • 2. Prior myocardial infarction, wall-motion-abnormalities, stenosis ≥50%
  • Prior cardiac surgery
  • More than mild left-sided valve disease
  • Documented pulmonary disease leading to dyspnea NYHA II or more, including history of asthma bronchiale
  • Any restrictive LV filling pattern without eccentric LV hypertrophy, such as in infiltrative myocardial diseases
Show all 10Show fewer
  • Pericardial diseases, including prior pericardiotomy and pericardial effusions.
  • Pacemaker, implantable cardioverter-defibrillator (ICD) or cardiac resynchronization therapy device (CRT)
  • Known adverse reactions to Dobutamin or Esmolol
  • Women who are pregnant or breast feeding (β-HCG > 10 IU/L)

Trial locations and contacts

1 site in 1 country.

Switzerland1 site
  • Departement of Cardiology, Bern University Hospital

    Bern, 3010

Other trials in Switzerland

About this study

It is known that, at the end of the cardiac ejection period, potential energy is stored in elastic fibers of the heart, which promotes the suction of blood from the atria during early filling. The investigators have developed a new ultrasound-based method to quantify this suction effect. Here, it is necessary to reduce the complex 3-dimensional cardiac mechanics in a 1-dimensional (piston-like) pump system. In the study, several steps of model reduction will be tested. Each reduction is intended to allow non-invasive measurements to become increasingly simple and feasible at reduced echo quality. The reference method is the invasive data obtained from a pressure-volume conductance catheter. To increase the supply of potential energy in the elastic fibers, a substance (dobutamine) is administered for transient strengthening of the force of contraction.

Hypothesis: There is a good agreement between the new, non-invasive parameters and the invasive reference method for the quantification of the suction effect of the left ventricle, and the good correlation persists even with increasing model simplification.

Read the detailed description

Background

  1. Clinical Background: Heart failure is a widespread cause of morbidity and mortality worldwide. Despite their similar clinical manifestation, systolic and diastolic heart failure are two distinct entities that differ with regard to pathophysiology, diagnosis, prognosis and treatment.

Diastolic dysfunction occurs early in the onset of heart failure. In the past, diastolic dysfunction has often been defined per exclusionem as heart failure in the absence of evidence of systolic dysfunction. This definition may be appropriate for clinical diagnosis if concentric or eccentric LV hypertrophy co-exists, but it is physiologically misleading, since diastolic dysfunction continues to persist or even worsens with the onset of systolic dysfunction. It should be considered that symptoms in heart failure are more closely related to diastolic than to systolic dysfunction. Furthermore, also prognosis of heart failure seems to be more closely related to the underlying degree of diastolic rather than systolic dysfunction. Despite its clinical importance, however, large trials on treatment outcome for diastolic heart failure (such as the CHARM-preserved and PEP-CHF trials) are scarce and disappointing. Among numerous others, three important reasons for this data scarcity are: overestimation of end-point events in the power analyses of the respective trials, lack of therapeutic agents that specifically target diastolic dysfunction, and lack of simple echocardiographic parameters capable of measuring diastolic function independently from loading conditions. The latter will be addressed in the study presented here. As will be detailed below, early-diastolic function is inextricably linked to the end-systolic conditions of the ventricle. An echocardiographic parameter describing an early-diastolic mechanical event is therefore very likely to vary with changes in end-systolic conditions. The present study will investigate new parameters of early-diastolic function by provoking contractility changes.

1.2 Physiological Background: There is no doubt that the human heart is a suction-pump capable of aspirating blood before expelling. There is a concept of early-diastolic suction: systolic myocardial shortening is believed to store potential energy in elastic fibers and myocyte filaments that are released in early-diastole to produce a suction effect, thus contributing to quick LV filling.

In 1930, Katz et al. first published a study describing a suction phenomenon in an in-vitro preparation of an isolated beating turtle ventricle. They showed that the early-diastolic volume increase of the ventricle coincides with a pressure fall, which is consistent with the concept of suction. He concluded that contraction and relaxation alters the elastic state of the ventricle between two limits (end-systolic and -diastolic), and proposed a suction effect produced by elastic recoil. This view represented a paradigm change, as filling was previously considered the result of atrial pressure. If suction is defined according to Katz, i.e. filling during pressure decay, then it is observed in all ejecting hearts, regardless of contractility, end-systolic volume or filling pressure. This type of suction corresponds to what early physiologists may have called the ventricular filling 'vis a fronte': a filling mechanism generated by the heart. It constitutes a suction effect relative to the filling reservoir. It can occur as a result of both, elastic recoil and relaxation.

In a physically more stringent concept, suction is defined as filling at negative LV transmural pressure. According to this definition, the ventricular wall performs work to pull blood into the cavity. There are two important conditions for such a suction event. First, the end-systolic volume must be lower than the volume of elastic ventricular equilibrium, otherwise no elastic energy would be stored. Second, early diastolic relaxation must be quick enough to allow restoring forces to prevail over the vanishing active forces. The process of suction lasts until the equilibrium volume is reached. Atrial pressure then stretches the ventricle to a volume where a force balance between filling pressure and ventricular passive stress impedes any further flow (diasthasis). Diasthasis volume is probably higher than the elastic equilibrium volume, which is a ventricular material property. Because LV filling itself very quickly abolishes any negative transmural pressures, and the equilibrium volume of the LV is probably small, suction according to this definition has been measured almost exclusively under particular circumstances, such as in nearly empty ventricles (e.g. artificially low afterload), during artificial absence of filling, or during inotropic stimulation.

1.3 Concept of Testing New Parameters: In the current study, several steps of model reduction will be tested. Each reduction is intended to allow non-invasive measurements to become increasingly simple and feasible at reduced echo quality. The comparison with the gold standard will then reveal the costs of model reductions in terms of precision and predictive power. Since direct pressure measurements are not feasible non-invasively, some simplifications of the pump model are mandatory. The most useful is to reduce the heart to a 1-dimensional, piston-like pump system moving only in apico-basal direction (longitudinal function). In such a model, not only contractions, but also flow directions are longitudinal. The 1-dimensional Euler equation can then be used to calculate instantaneous atrio-ventricular pressure gradients from Color Doppler M-Mode echocardiograms. Similarly, apico-basal displacement of the 'piston' can easily be measured by M-Mode echocardiograms of the mitral annulus (mitral annular plane systolic excursion, MAPSE). When combined, the suction effect of the ventricle relative to the left atrium can be assessed. A further simplification consists of replacing MAPSE by the widely used Doppler tissue imaging (DTI) -parameters of systolic (s') and early-diastolic (e') velocity. The reference method of this study will consist of invasively measured suction work, against which the new parameters will directly be compared.

Objective

The study is performed to prospectively test novel, non-invasive parameters of early diastolic function with respect to their ability to quantify the physiological phenomenon of LV suction.

Hypothesis: The following parameters correlate significantly with LV suction work, but in descending order of magnitude (r2): absolute suction work from pressure/MAPSE, relative suction work from IVPG/MAPSE, e'/L0, e'/s', (at rest and under Dobutamin).

Methods

Reference for LV suction work: conductance-catheter is introduced through the aortic valve and placed along the longitudinal axis of the LV. Continuous conductance are transformed into LV volume data and simultaneous pressure measurements are performed.

Echo parameters:

IVPG (intraventricular pressure gradients)is calculated from Color-Doppler M-Mode echocardiograms. This imaging modality produces a color-coded, longitudinal forward-flow velocity profile (y-axis) over time (x-axis). Such velocity maps can then be processed to retrieve instantaneous pressure gradients between any two points on the longitudinal axis.

MAPSE (mitral annular plane systolic excursion)is performed with M-Mode echocardiogram of the septal and lateral mitral annulus.

Tissue velocity: peak systolic velocity (s') and the peak early-diastolic negative velocity (e')of septal and lateral mitral anulus are measured by pulsed-wave Doppler tissue imaging (DTI).

Keywords
suction work
Medical subject headings
Heart Failure, Diastolic

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

Study groups in NCT02315859
Study groupRoleWhat they receive
All patientsAll patients

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Composite outcome measure: absolute suction work using MAPSE (Mitral annular plane systolic excursion) and IVPG (Intraventricular pressure gradients)

    Measured: During the cardiac catheterization: at rest, under Dobutamin 20ug/kg, under Dobutamin 40ug/kg (expected average duration of 20 minutes); no follow-up.

Secondary outcomes (4)
  1. Composite outcome measure: absolute suction work using MAPSE and catheter-derived invasive pressure

    Measured: During the cardiac catheterization: at rest, under Dobutamin 20ug/kg, under Dobutamin 40ug/kg (expected average duration of 20 minutes); no follow-up.

  2. Composite outcome measure: absolute suction work using impedance catheter-derived volumes and IVPG

    Measured: During the cardiac catheterization: at rest, under Dobutamin 20ug/kg, under Dobutamin 40ug/kg (expected average duration of 20 minutes); no follow-up.

  3. Absolute suction work using tissue velocities (e'/s')

    Measured: During the cardiac catheterization: at rest, under Dobutamin 20ug/kg, under Dobutamin 40ug/kg (expected average duration of 20 minutes); no follow-up.

  4. Absolute suction work using tissue velocities (s'/L0, L0 = end-systolic ventricular length)

    Measured: During the cardiac catheterization: at rest, under Dobutamin 20ug/kg, under Dobutamin 40ug/kg (expected average duration of 20 minutes); no follow-up.

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted12 Dec 2014 (estimated)
  2. Study start31 Dec 2014
  3. Primary completion31 Dec 2016
  4. Study completion30 Jun 2017

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Case only
Time perspective
Prospective
Enrolment
40 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT02315859
Sponsor's protocol ID
089/14
Status last verified
Mar 2023
First submitted
2 Dec 2014
Last updated
28 Mar 2023
Results posted
No
Data monitoring committee
No

Questions about this trial

What is this clinical trial studying?

An observational study of Diastolic Heart Failure, run by Insel Gruppe AG, University Hospital Bern at 1 site in Switzerland.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 10 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 28 Mar 2023. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Switzerland. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Composite outcome measure: absolute suction work using MAPSE (Mitral annular plane systolic excursion) and IVPG (Intraventricular pressure gradients) (time frame: During the cardiac catheterization: at rest, under Dobutamin 20ug/kg, under Dobutamin 40ug/kg (expected average duration of 20 minutes); no follow-up.). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 28 Mar 2023.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in